Company Overview - Proactive is a financial news publisher that provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The company has a team of experienced and qualified news journalists who produce independent content [2] Market Focus - Proactive specializes in medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [3] - The news team delivers insights across various sectors including biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [3] Technology Adoption - Proactive is recognized for its forward-looking approach and enthusiastic adoption of technology to enhance workflows [4] - The company utilizes automation and software tools, including generative AI, while ensuring that all content is edited and authored by humans [5]

Company Overview - Serina Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing a pipeline of drug candidates for neurological diseases and other indications, utilizing its proprietary POZ Platform for drug optimization [5]. Leadership Appointment - Dr. Stephen Brannan has been appointed to the Board of Directors, bringing over 30 years of experience in neuroscience and neuropsychiatry drug development [2][3]. - Dr. Brannan previously served as Chief Medical Officer at Karuna Therapeutics, where he led the clinical strategy for KarXT, a groundbreaking therapy for schizophrenia that contributed to Karuna's $14 billion acquisition by Bristol Myers Squibb in 2024 [2][3]. Strategic Focus - The company aims to advance long-acting treatments for movement disorders and other CNS conditions, aligning with Dr. Brannan's expertise in designing data-driven clinical trials and understanding patient and commercial needs [3]. Previous Experience - Dr. Brannan has held senior roles at Takeda, Novartis, Cyberonics (now LivaNova), and Eli Lilly, directing clinical development programs in various CNS conditions [3]. - He is a founding member of the CNS Summit Leadership Council and has served on the Executive Committee of the International Society for CNS Clinical Trials and Methodology (ISCTM) [3]. Board Changes - Remy Gross has departed from the Board of Directors, with the company expressing gratitude for his contributions during its transition from a private to a public entity [5].

This presentation by Contineum Therapeutics, Inc. ("Contineum", "We" or "Our) contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, including without limitation statements regarding our future results of operations and financial position, future revenue, timing, progress and expected results of our clinical trials and our product development efforts, business strategy, prospects, research and development costs, timing and likelihood of ...

VANCOUVER, British Columbia and BOSTON, May 14, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced that the company will present at the 2025 RBC Capital Markets Global Healthcare Conference taking place in New York, NY from May 20-21, 2025. Fireside Chat Presentation Details: Date: Wednesday, May 21, 2025 Time: 10:30-10:55 AM ...

Neumora Therapeutics (NMRA) Q1 2025 Earnings Call May 12, 2025 04:30 PM ET Company Participants Helen Rubinstein - VP-IR and Corporate CommunicationsPaul Berns - Co-Founder, Executive Chairman and Chief Executive OfficerJoshua Pinto - PresidentBill Aurora - Chief Operating & Development OfficerMichael Milligan - CFODouglas Tsao - Managing DirectorBrian Abrahams - MD & Global Sector Head - Health Care ResearchGraig Suvannavejh - Managing DirectorJohn Boyle - Biotechnology Equity Research AssociatePoorna Kann ...

Neumora Therapeutics (NMRA) Q1 2025 Earnings Call May 12, 2025 04:30 PM ET Speaker0 Ladies and gentlemen, thank you for standing by. At this time, all participants are in a listen only mode. After the speakers' presentation, there will be a question and answer session. Please be advised that today's conference is being recorded. I would now like to turn the conference over to Helen Rubinstein, Vice President of Investor Relations and Communications. Please go ahead. Speaker1 Good afternoon, and thank you fo ...

On track to report topline data from NMRA-511 in Alzheimer’s disease agitation around the end of 2025 Resumed enrollment for KOASTAL-3 and -2 studies in March 2025; anticipate reporting topline major depressive disorder data from KOASTAL-3 in the first quarter of 2026 and -2 in the second quarter of 2026 Expect to progress M4 positive allosteric modulator (PAM) program into the clinic in mid-2025 Secured $125 million venture debt facility from K2 HealthVentures, with $40 million available in 2025; cash runw ...

Advancing Life-Changing Discoveries in Neuroscience Neurocrine Biosciences (Nasdaq: NBIX) Q1 2025 Earnings Presentation May 5,2025 Safe Harbor and Forward-Looking Statements In addition to historical facts, this presentation contains forward-looking statements that involve a number of risks and uncertainties. These statements include, but are not limited to, statements related to: the benefits to be derived from our products and product candidates; the value our products and/or our product candidates may br ...

Rapport Therapeutics (RAPP) Conference Summary Company Overview - **Company**: Rapport Therapeutics - **CEO**: Abe Sisan, with over 20 years in the biotech sector, previously president of Cerevel Therapeutics [doc id='4'][doc id='5'] - **CFO**: Troy Nelzi, with extensive experience in finance and business development, raised approximately $5 billion for eight approved products [doc id='3'] Industry Focus - **Sector**: Biotech, specifically in neuroscience and anti-seizure medications - **Key Product**: RAP two one nine (RAP-219), a TARP gamma eight AMPA modulator targeting focal epilepsy [doc id='7'][doc id='10'] Core Scientific Insights - **Receptor Associated Proteins (RAPs)**: Critical for regulating receptor function and signal transduction, allowing for targeted modulation of AMPA receptors [doc id='6'][doc id='8'] - **Differentiation**: RAP-219 aims to achieve significant seizure suppression without common adverse effects like sedation or motor impairment, presenting a potentially unprecedented therapeutic index [doc id='10][doc id='11'] Clinical Development - **Preclinical Evidence**: High probability of success in translating preclinical findings to clinical efficacy in epilepsy, with RAP-219 showing significant efficacy across various models [doc id='12'] - **Phase 2a Trial**: Utilizing an RNS device for objective measurement of efficacy, focusing on long episodes as a biomarker for seizure activity [doc id='15][doc id='16'] - **Expected Outcomes**: Aiming for a 30% reduction in long episodes correlating with at least a 50% reduction in clinical seizures, with results expected in Q3 2025 [doc id='31][doc id='34] Community Engagement and Feedback - **Interest from KOLs**: Significant interest in the trial design and methodology, viewed as a step forward in drug development for epilepsy [doc id='26][doc id='27'] - **Data Presentation**: Recent presentations at the American Academy of Neurology meeting highlighted the predictive value of long episode reductions for clinical seizure outcomes [doc id='28][doc id='29] Future Directions - **Next Steps**: If data is positive, plans to move into parallel Phase 2b/3 registrational trials [doc id='35] - **Pipeline Expansion**: Plans to initiate studies for bipolar mania and neuropathic pain, with data expected in early 2027 for bipolar mania [doc id='40] Conclusion - Rapport Therapeutics is positioned to potentially transform the treatment landscape for epilepsy and other neurological conditions through its innovative approach to drug development and its focus on precision neuroscience [doc id='39]

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Q4 2024 Results Conference Call February 26, 2025 4:30 PM ET Company Participants Al Kildani - SVP of Investor Relations & Corporate Communications Catherine Owen Adams - CEO Tom Garner - COO Elizabeth Thompson - EVP, Head of R&D Mark Schneyer - EVP, CFO Conference Call Participants Ami Fadia - Needham & Company Tessa Romero - JPMorgan Joel Beatty - Baird Tazeen Ahmad - Bank of America Securities Gregory Renza - RBC Capital Markets Charles Duncan - Cantor Sumant Kul ...